Gethyn Mon
@gethynmon.bsky.social
Reposted by Gethyn Mon
This is well known in medicine. It’s why there are dozens of beta-blockers (which people will take for decades) and there hasn’t been an entirely new antibiotic in 40 years. That isn’t where the money is made.
Goldman Sachs analysts : The money men saying the quiet part out loud
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
www.cnbc.com
December 19, 2024 at 1:14 PM
This is well known in medicine. It’s why there are dozens of beta-blockers (which people will take for decades) and there hasn’t been an entirely new antibiotic in 40 years. That isn’t where the money is made.